cisplatin,pembrolizumab,gemcitabine,pemetrexed,nivolumab,Toripalimab,Ipilimumab,Atezolizumab
merck,Shanghai Junshi Bioscience,Coherus,BMS,roche
['kn671']
the #oncoalerttoptweet day 2 #asco23 tweet by partner superb discussion of kn671 by where he highlights pro s and con s of the major questions from this study: - rationale or adj io based on pcr - use of neoadj chemoio in 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨